Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDerwent London Regulatory News (DLN)

Share Price Information for Derwent London (DLN)

Share Price is delayed by 15 minutes
Get Live Data
1,765.00    -13.00 (-0.73%)
Bid:
1,768.00
Ask:
1,771.00
Spread: 3.00 (0.17%)
Market Cap: £1.98b
DLN Live PriceLast checked at - London Stock Exchange

Intraday Derwent London Share Chart

Acquisition

3 Dec 2024 07:00

RNS Number : 5001O
Derwent London PLC
03 December 2024
 

3 December 2024

Derwent London plc ("Derwent London" / "the Group") Acquisition of remaining 50% in 50 Baker Street W1 scheme

Derwent London is pleased to announce that it has acquired the remaining 50% stake in its proposed 50 Baker Street W1 scheme from Lazari Investments, its joint venture partner, for £44.4m (£370 psf on consented floor area). This reflects a 4.2% net initial yield at the current passing income of £2.0m pa (based on 50%). Resolution to grant planning consent for a c.240,000 sq ft office-led scheme, which is nearly double the existing floor area, was received in August 2024. Detailed design work is underway.

 

The decision to acquire full control of 50 Baker Street was taken following the pre-letting success at our adjacent 25 Baker Street W1 project and reflects our ongoing confidence in the strength of the West End occupational market. Good progress is being made on a regear of the headleases with The Portman Estate, our freeholder and the owner of 64 Baker Street, to facilitate delivery of this exciting project. This follows our previous regear in 2021 with The Portman Estate at 25 Baker Street. We expect the scheme to deliver an attractive return in line with our current on-site projects.

 

Paul Williams, Chief Executive of Derwent London, said:

"West End vacancy remains low and demand from high quality occupiers across a broad range of business sectors continues to outpace supply. Underpinned by our confidence that the property cycle has inflected, we believe now is the time to acquire well-located regeneration opportunities. Our decision to take full ownership of 50 Baker Street reflects this and marks the conclusion of a successful partnership with Lazari. We look forward to progressing the project to the next stage, with works expected to commence on site in H1 2026."

 

Nicholas Lazari, Director of Lazari Investments, said:

"The sale of our 50% interest in 50 Baker Street marks the culmination of a successful partnership with Derwent London. Following receipt of the resolution to grant planning in August and having made good progress on the regear with The Portman Estate, we feel the time is right to capitalise on our efforts. The cash proceeds from the sale ensures that the equity requirements for our exciting and extensive West End development pipeline are now fully funded and puts us in a strong position to realise opportunities that may arise."

 

 

For further information, please contact:

 

Derwent London

Tel: +44 (0)20 3478 4217 (Robert Duncan)

 

Paul Williams, Chief Executive

Richard Dean, Director of Investment

Robert Duncan, Head of Investor Relations

 

Brunswick Group

Tel: +44 (0)20 7404 5959

 

Nina Coad

Peter Hesse

 

 

Notes to editors

Derwent London plc

Derwent London plc owns 63 buildings in a commercial real estate portfolio predominantly in central London valued at £4.8 billion as at 30 June 2024, making it the largest London office-focused real estate investment trust (REIT).

Our experienced team has a long track record of creating value throughout the property cycle by regenerating our buildings via redevelopment or refurbishment, effective asset management and capital recycling. We typically acquire central London properties off-market with low capital values and modest rents in improving locations, most of which are either in the West End or the Tech Belt. We capitalise on the unique qualities of each of our properties - taking a fresh approach to the regeneration of every building with a focus on anticipating tenant requirements and an emphasis on design. Reflecting and supporting our long-term success, the business has a strong balance sheet with modest leverage, a robust income stream and flexible financing.

We are frequently recognised in industry awards for the quality, design and innovation of our projects. Landmark buildings in our 5.3 million sq ft portfolio include 1 Soho Place W1, 80 Charlotte Street W1, Brunel Building W2, White Collar Factory EC1, Angel Building EC1, 1-2 Stephen Street W1, Horseferry House SW1 and Tea Building E1.

As part of our commitment to lead the industry in mitigating climate change, Derwent London has committed to becoming a net zero carbon business by 2030, publishing its pathway to achieving this goal in July 2020. Our science-based carbon targets validated by the Science Based Targets initiative (SBTi). In 2013 the Company launched a voluntary Community Fund which has to date supported over 160 community projects in the West End and the Tech Belt.

The Company is a public limited company, which is listed on the London Stock Exchange and incorporated and domiciled in the UK. The address of its registered office is 25 Savile Row, London, W1S 2ER.

For further information see www.derwentlondon.com or follow us on LinkedIn

 

 

Forward-looking statements

This document contains certain forward-looking statements about the future outlook of Derwent London. By their nature, any statements about future outlook involve risk and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future. Actual results, performance or outcomes may differ materially from any results, performance or outcomes expressed or implied by such forward-looking statements.

No representation or warranty is given in relation to any forward-looking statements made by Derwent London, including as to their completeness or accuracy. Derwent London does not undertake to update any forward-looking statements whether as a result of new information, future events or otherwise. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQTTBPTMTMMBPI
Date   Source Headline
12th Aug 20257:00 amRNSInterim Results
5th Aug 20257:00 amRNSNew headlease agreed at 50 Baker Street W1
31st Jul 20254:45 pmRNSTotal Voting Rights
29th Jul 20257:00 amRNSDisposal of Francis House SW1 for £55.5m
25th Jul 20257:00 amRNSExtension of £450m Revolving Credit Facility
30th Jun 20254:45 pmRNSTotal Voting Rights
18th Jun 20257:00 amRNSAdobe lease extension and expansion
12th Jun 202511:00 amRNSRedemption of £175 million Convertible Bonds
30th May 20254:45 pmRNSTotal Voting Rights
29th May 202511:15 amRNSHolding(s) in Company
23rd May 20254:05 pmRNS£250m 7-year 5.25% bond issuance
16th May 202512:00 pmRNSResults of 2025 Annual General Meeting
8th May 20257:00 amRNSFirst Quarter Business Update
1st May 202510:00 amRNSAnnual Bondholder Meeting
30th Apr 20254:45 pmRNSTotal Voting Rights
15th Apr 202510:00 amRNSAnnual Financial Report
9th Apr 20253:00 pmRNSAdditional Listing
31st Mar 20254:45 pmRNSTotal Voting Rights
31st Mar 202510:00 amRNSNotice of Q1 2025 Business Update
26th Mar 20251:00 pmRNSDirector/PDMR Shareholding
20th Mar 20254:45 pmRNSBlock listing Interim Review
7th Mar 20252:00 pmRNSDirector/PDMR Shareholding
4th Mar 20255:15 pmRNSDirector/PDMR Shareholding
28th Feb 20254:45 pmRNSTotal Voting Rights
27th Feb 20257:00 amRNSResults for the Year Ended 31 December 2024
31st Jan 20254:45 pmRNSTotal Voting Rights
30th Jan 20255:35 pmRNSHolding(s) in Company
27th Jan 20251:30 pmRNSHolding(s) in Company
9th Jan 20257:00 amRNS25 Baker Street W1 offices fully pre-let
31st Dec 202412:45 pmRNSTotal Voting Rights
3rd Dec 20247:00 amRNSAcquisition
29th Nov 20244:45 pmRNSTotal Voting Rights
7th Nov 20247:00 amRNSTHIRD QUARTER BUSINESS UPDATE
5th Nov 202412:44 pmRNSHolding(s) in Company
31st Oct 20244:45 pmRNSTotal Voting Rights
23rd Oct 20245:30 pmRNSHolding(s) in Company
16th Oct 202410:30 amRNSDirectorate Change
30th Sep 20244:45 pmRNSTotal Voting Rights
20th Sep 20244:45 pmRNSBlock listing Interim Review
19th Sep 202411:00 amRNSDirector/PDMR Shareholding
17th Sep 202411:03 amRNSHolding(s) in Company
30th Aug 20244:45 pmRNSTotal Voting Rights
23rd Aug 202411:15 amRNSAdditional Listing
8th Aug 20247:00 amRNSHalf-Year Results
31st Jul 20244:45 pmRNSTotal Voting Rights
28th Jun 20244:45 pmRNSTotal Voting Rights
12th Jun 202411:00 amRNSHolding(s) in Company
10th Jun 20244:00 pmRNSDirector/PDMR Shareholding
31st May 20244:45 pmRNSTotal Voting Rights
31st May 202410:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.